US 12,441,998 B2
SLC2A1 lncRNA as a biologic and related treatments and methods
Umrao Monani, Oradell, NJ (US); and Maoxue Tang, New York, NY (US)
Assigned to The Trustees of Columbia University in the City of New York, New York, NY (US)
Appl. No. 16/755,484
Filed by The Trustees of Columbia University in the City of New York, New York, NY (US)
PCT Filed Oct. 12, 2018, PCT No. PCT/US2018/055599
§ 371(c)(1), (2) Date Apr. 10, 2020,
PCT Pub. No. WO2019/075320, PCT Pub. Date Apr. 18, 2019.
Claims priority of provisional application 62/571,667, filed on Oct. 12, 2017.
Prior Publication US 2021/0222167 A1, Jul. 22, 2021
Int. Cl. C12N 15/113 (2010.01); A61K 35/76 (2015.01); A61P 3/08 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 35/76 (2013.01); A61P 3/08 (2018.01); C12N 2310/111 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A recombinant adeno-associated virus (rAAV) vector comprising a nucleic acid comprising a SLC2A1-NAT (Solute Carrier Family 2, or Glucose transporter 1 (Glut1), natural antisense transcript) sequence consisting of the nucleotide sequence of SEQ ID NO: 1.